Key Insights

Highlights

Success Rate

85% trial completion

Published Results

114 trials with published results (16%)

Research Maturity

300 completed trials (43% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

7.3%

51 terminated out of 699 trials

Success Rate

85.5%

-1.1% vs benchmark

Late-Stage Pipeline

14%

96 trials in Phase 3/4

Results Transparency

38%

114 of 300 completed with results

Key Signals

114 with results85% success51 terminated

Data Visualizations

Phase Distribution

525Total
Not Applicable (115)
Early P 1 (17)
P 1 (164)
P 2 (133)
P 3 (61)
P 4 (35)

Trial Status

Completed300
Recruiting131
Unknown107
Terminated51
Not Yet Recruiting39
Active Not Recruiting35

Trial Success Rate

85.5%

Benchmark: 86.6%

Based on 300 completed trials

Clinical Trials (699)

Showing 20 of 20 trials
NCT07180537Not ApplicableRecruiting

Creating Health Course Study for People With Rheumatological Conditions and Mood Disorders

NCT06161116Phase 2TerminatedPrimary

Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)

NCT06977724Phase 1Recruiting

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)

NCT00055055Completed

Study of Families With Twins or Siblings Discordant for Rheumatic Disorders

NCT04976322Phase 3Enrolling By InvitationPrimary

A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

NCT06570798Phase 2RecruitingPrimary

A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

NCT07751315Phase 1Not Yet RecruitingPrimary

A Study of QLS2404 Injection in Healthy Participants and Participants With Rheumatic Autoimmune Diseases

NCT06617325Phase 3RecruitingPrimary

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

NCT05039840Phase 2Active Not RecruitingPrimary

Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus

NCT07409181Phase 2RecruitingPrimary

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

NCT07748156Early Phase 1Not Yet RecruitingPrimary

SNC116 Therapy for Refractory Systemic Lupus Erythematosus

NCT05799378Phase 3RecruitingPrimary

Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

NCT06984341Phase 1WithdrawnPrimary

A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)

NCT00001372RecruitingPrimary

Study of Systemic Lupus Erythematosus

NCT05869955Phase 1Active Not RecruitingPrimary

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

NCT07363590Phase 1RecruitingPrimary

A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)

NCT06333483Phase 1Active Not RecruitingPrimary

Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus

NCT03816345Phase 1Recruiting

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

NCT04895696Phase 2Active Not RecruitingPrimary

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

NCT07201558Phase 1Recruiting

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

Scroll to load more

Research Network

Activity Timeline